Timing is critical for an effective Anti-Metastatic immunotherapy: The decisive role of IFNγ/STAT1-Mediated activation of autophagy

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Yan, Jun ^a   Wang, Zi Yan ^a   Yang, Hong Zhen ^a   Liu, Han Zhi ^a   Mi, Su ^a   Lv, Xiao Xi ^a   Fu, Xiao Ming ^a   Yan, Hui Min ^a   Zhang, Xiao Wei ^a   Zhan, Qi Min ^b   Hu, Zhuo Wei ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

^b CANCER HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; GAMMA INTERFERON; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; RAPAMYCIN; STAT1 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CELL DEATH; COMPLEX FORMATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; FEMALE; GENE ACTIVATION; GENE REPRESSION; IMMUNOLOGICAL TOLERANCE; MELANOMA; MELANOMA CELL; METASTASIS INHIBITION; MOUSE; NONHUMAN; TUMOR IMMUNITY; ANIMAL; APOPTOSIS; C57BL MOUSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETICS; IMMUNOTHERAPY; LUNG; METABOLISM; METASTASIS; METHODOLOGY; PATHOLOGY; PHYSIOLOGY; TIME; TRANSMISSION ELECTRON MICROSCOPY; TUMOR CELL LINE; ULTRASTRUCTURE; WESTERN BLOTTING;

MUS;

ANIMALS; APOPTOSIS; AUTOPHAGY; BLOTTING, WESTERN; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; IMMUNOTHERAPY; INTERFERON-GAMMA; LUNG; MELANOMA; MICE; MICE, INBRED C57BL; MICROSCOPY, ELECTRON, TRANSMISSION; NEOPLASM METASTASIS; STAT1 TRANSCRIPTION FACTOR; TIME FACTORS;

EID: 80052731707     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024705     Document Type: Article

References (44)

1. Kopfstein L, Christofori G, (2006) Metastasis: cell-autonomous mechanisms versus contributions by the tumor microenvironment. Cell Mol Life Sci 63: 449-468.
2. de Visser KE, Eichten A, Coussens LM, (2006) Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6: 24-37.
3. Blattman JN, Greenberg PD, (2004) Cancer immunotherapy: a treatment for the masses. Science 305: 200-205.
4. Ruttinger D, Winter H, van den Engel NK, Hatz R, Jauch KW, et al. (2010) Immunotherapy of cancer: key findings and commentary on the third Tegernsee conference. Oncologist 15: 112-118.
5. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71-96.
6. Lasaro MO, Ertl HC, (2010) Targeting inhibitory pathways in cancer immunotherapy. Curr Opin Immunol 22: 385-390.
7. Rubartelli A, Lotze MT, (2007) Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol 28: 429-436.
8. Romagne F, (2007) Current and future drugs targeting one class of innate immunity receptors: the Toll-like receptors. Drug Discov Today 12: 80-87.
9. Kanzler H, Barrat FJ, Hessel EM, Coffman RL, (2007) Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 13: 552-559.
10. Fournier P, Schirrmacher V, (2009) Randomized clinical studies of anti-tumor vaccination: state of the art in 2008. Expert Rev Vaccines 8: 51-66.
11. Klinman D, Shirota H, Tross D, Sato T, Klaschik S, (2008) Synthetic oligonucleotides as modulators of inflammation. J Leukoc Biol 84: 958-964.
12. Schmidt C, (2007) Clinical setbacks for toll-like receptor 9 agonists in cancer. Nat Biotechnol 25: 825-826.
13. Theiner G, Rossner S, Dalpke A, Bode K, Berger T, et al. (2008) TLR9 cooperates with TLR4 to increase IL-12 release by murine dendritic cells. Mol Immunol 45: 244-252.
14. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A, (2005) Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 6: 769-776.
15. Yang HZ, Cui B, Liu HZ, Mi S, Yan J, et al. (2009) Blocking TLR2 activity attenuates pulmonary metastases of tumor. PLoS One 4: e6520.
16. Liu YY, Cai WF, Yang HZ, Cui B, Chen ZR, et al. (2008) Bacillus Calmette-Guerin and TLR4 agonist prevent cardiovascular hypertrophy and fibrosis by regulating immune microenvironment. J Immunol 180: 7349-7357.
17. Noguchi M, Imaizumi K, Kawabe T, Wakayama H, Horio Y, et al. (2001) Induction of antitumor immunity by transduction of CD40 ligand gene and interferon-gamma gene into lung cancer. Cancer Gene Ther 8: 421-429.
18. Hahnel PS, Thaler S, Antunes E, Huber C, Theobald M, et al. (2008) Targeting AKT signaling sensitizes cancer to cellular immunotherapy. Cancer Res 68: 3899-3906.
19. Burdelya L, Catlett-Falcone R, Levitzki A, Cheng F, Mora LB, et al. (2002) Combination therapy with AG-490 and interleukin 12 achieves greater antitumor effects than either agent alone. Mol Cancer Ther 1: 893-899.
20. Ho HH, Ivashkiv LB, (2006) Role of STAT3 in type I interferon responses. Negative regulation of STAT1-dependent inflammatory gene activation. J Biol Chem 281: 14111-14118.
21. Salazar M, Carracedo A, Salanueva IJ, Hernandez-Tiedra S, Lorente M, et al. (2009) Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J Clin Invest 119: 1359-1372.
22. Kim HS, Lee MS, (2007) STAT1 as a key modulator of cell death. Cell Signal 19: 454-465.
23. Yu H, Pardoll D, Jove R, (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9: 798-809.
24. Chang YP, Tsai CC, Huang WC, Wang CY, Chen CL, et al. (2010) Autophagy facilitates IFN-gamma-induced Jak2-STAT1 activation and cellular inflammation. J Biol Chem 285: 28715-28722.
25. Delgado MA, Deretic V, (2009) Toll-like receptors in control of immunological autophagy. Cell Death Differ 16: 976-983.
26. Singh SB, Davis AS, Taylor GA, Deretic V, (2006) Human IRGM induces autophagy to eliminate intracellular mycobacteria. Science 313: 1438-1441.
27. Bafica A, Feng CG, Santiago HC, Aliberti J, Cheever A, et al. (2007) The IFN-inducible GTPase LRG47 (Irgm1) negatively regulates TLR4-triggered proinflammatory cytokine production and prevents endotoxemia. J Immunol 179: 5514-5522.
28. Mizushima N, Yoshimori T, Levine B, (2010) Methods in mammalian autophagy research. Cell 140: 313-326.
29. Jin S, White E, (2007) Role of autophagy in cancer: management of metabolic stress. Autophagy 3: 28-31.
30. Cully M, You H, Levine AJ, Mak TW, (2006) Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 6: 184-192.
31. Umansky V, Malyguine A, Shurin M, (2009) New perspectives in cancer immunotherapy and immunomonitoring. Future Oncol 5: 941-944.
32. Curiel TJ, (2007) Tregs and rethinking cancer immunotherapy. J Clin Invest 117: 1167-1174.
33. Avraham R, Benish M, Inbar S, Bartal I, Rosenne E, et al. (2010) Synergism between immunostimulation and prevention of surgery-induced immune suppression: an approach to reduce post-operative tumor progression. Brain Behav Immun 24: 952-958.
34. Raman VS, Bhatia A, Picone A, Whittle J, Bailor HR, et al. (2010) Applying TLR synergy in immunotherapy: implications in cutaneous leishmaniasis. J Immunol 185: 1701-1710.
35. Rosenberg SA, Yang JC, Restifo NP, (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10: 909-915.
36. Molavi O, Ma Z, Hamdy S, Lai R, Lavasanifar A, et al. (2008) Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model. Immunol Cell Biol 86: 506-514.
37. Kortylewski M, Kujawski M, Herrmann A, Yang C, Wang L, et al. (2009) Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy. Cancer Res 69: 2497-2505.
38. Marx J, (2006) Autophagy: is it cancer's friend or foe? Science 312: 1160-1161.
39. Kenific CM, Thorburn A, Debnath J, (2010) Autophagy and metastasis: another double-edged sword. Curr Opin Cell Biol 22: 241-245.
40. Li JC, Au KY, Fang JW, Yim HC, Chow KH, et al. (2011) HIV-1 trans-activator protein dysregulates IFN-gamma signaling and contributes to the suppression of autophagy induction. AIDS 25: 15-25.
41. Van Grol J, Subauste C, Andrade RM, Fujinaga K, Nelson J, et al. (2011) HIV-1 inhibits autophagy in bystander macrophage/monocytic cells through Src-Akt and STAT3. PLoS One 5: e11733.
42. Park HJ, Lee SJ, Kim SH, Han J, Bae J, et al. (2011) IL-10 inhibits the starvation induced autophagy in macrophages via class I phosphatidylinositol 3-kinase (PI3K) pathway. Mol Immunol 48: 720-727.
43. Deretic V, (2009) Multiple regulatory and effector roles of autophagy in immunity. Curr Opin Immunol 21: 53-62.
44. Sinnberg T, Lasithiotakis K, Niessner H, Schittek B, Flaherty KT, et al. (2009) Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide. J Invest Dermatol 129: 1500-1515.